Mach-1 Financial Group’s Blueprint Medicines BPMC Stock Holding History

Mach-1 Financial Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6	Closed	–	–	220
2021 Q4	$0	Buy	+6	New	+$628	﹤0.01%	246

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Mach-1 Financial Group's BPMC Position: Q1 2022 in Review

Mach-1 Financial Group sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 6 shares.

Mach-1 Financial Group first reported a position in BPMC in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

Mach-1 Financial Group reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
Mach-1 Financial Group sold 6 Blueprint Medicines shares in Q1 2022.
Mach-1 Financial Group first reported a position in Blueprint Medicines in Q4 2021 and held it in 1 quarter.
Mach-1 Financial Group's Blueprint Medicines position peaked at $0 in Q4 2021.
248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Mach-1 Financial Group's 13F filing for Q1 2022, filed 6 May 2022.